Improving the treatment of hepatitis C infection in the UK

Bibliography

• WHO: Hepatitis C- global prevalence (update). Weekly Epidemiology Record (1999) 74:425-427.
   PubMedGoogle Scholar
• ADES AE, PARKER S, WALKER J et al.: HCV prevalence in pregnant women in the UK. Epidemiol. Infect. (2000) 125:399-405.
   PubMed Web of Science ®Google Scholar
• BALOGUN MA, RAMSAY ME, PARRY JV et al.: The prevalence and genetic diversity of hepatitis C infection in antenatal clinic attenders in two regions of England. Epidemiol. Infect. (2000) 125:705-712.
   PubMed Web of Science ®Google Scholar
• BALOGUN MA, RAMSAY ME, HESKETH LM et al.: The prevalence of hepatitis C in England and Wales. J. Infect. (2002) 45:219-226.
   PubMed Web of Science ®Google Scholar
• HPA: Hepatitis C in England: the first Health Protection Agency annual report. Health Protection Agency Centre for Infections, London (2005).
   Google Scholar
• ROSENBERG W: The UK v Europe: losing the fight against hepatitis C. The Hepatitis C Trust (2005).
   Google Scholar
• DOH: Hepatitic C Action Plan for England. Department of Health, London (2004).
   Google Scholar
• DOH: Hepatitis C strategy for England. Department of Health, London (2002).
   Google Scholar
• NICE: Inteferon-α (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C. Technology Appraisal 75. NHS (2004).
   Google Scholar
• LAU DT, KLEINER DE, GHANY MG et al.: 10-Year follow-up after interferon-α therapy for chronic hepatitis C. Hepatology (1998) 28:1121-1127.
   PubMed Web of Science ®Google Scholar
• MARCELLIN P, BOYER N, GERVAIS A et al.: Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-α therapy. Ann. Intern. Med. (1997) 127:875-881.
   PubMed Web of Science ®Google Scholar
• SORIANO V, MAIDA I, NUNEZ M et al.: Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies. Antivir. Ther. (2004) 9:987-992.
   PubMed Web of Science ®Google Scholar
• TSUDA N, YUKI N, MOCHIZUKI K et al.: Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. J. Med. Virol. (2004) 74:406-413.
   PubMed Web of Science ®Google Scholar
• HADZIYANNIS SJ, SETTE H, JR, MORGAN TR et al.: Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. (2004) 140:346-355.
   PubMed Web of Science ®Google Scholar
• FRIED MW, SHIFFMAN ML, REDDY KR et al.: Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. (2002) 347:975-982.
   PubMed Web of Science ®Google Scholar
• MANNS MP, MCHUTCHISON JG, GORDON SC et al.: Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 358:958-965.
   PubMed Web of Science ®Google Scholar
• ZEUZEM S, HEATHCOTE EJ, SHIFFMAN ML et al.: Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon α for chronic hepatitis C. J. Hepatol. (2003) 39:106-111.
   PubMed Web of Science ®Google Scholar
• DAVIS GL, WONG JB, MCHUTCHISON JG et al.: Early virologic response to treatment with peginterferon α-2b plus ribavirin in patients with chronic hepatitis C. Hepatology (2003) 38:645-652.
   PubMed Web of Science ®Google Scholar
• LIU LW, TOMLINSON G, MAZZULLI T et al.: Early prediction of nonresponders to treatment with interferon α-2b and ribavirin in patients with chronic hepatitis C. Can. J. Gastroenterol. (2003) 17:483-487.
   PubMedGoogle Scholar
• ZEUZEM S, BUTI M, FERENCI P et al.: Efficacy of 24 weeks treatment with peginterferon α-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J. Hepatol. (2006) 44:97-103.
   PubMed Web of Science ®Google Scholar
• MUIR AJ, BORNSTEIN JD, KILLENBERG PG: Peginterferon α-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N. Engl. J. Med. (2004) 350:2265-2271.
   PubMed Web of Science ®Google Scholar
• SIDDIQUE I, EL-NAGA HA, MADDA JP et al.: Sampling variability on percutaneous liver biopsy in patients with chronic hepatitis C virus infection. Scand. J. Gastroenterol. (2003) 38:427-432.
   PubMed Web of Science ®Google Scholar
• SANDRIN L, FOURQUET B, HASQUENOPH JM et al.: Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med. Biol. (2003) 29:1705-1713.
   PubMed Web of Science ®Google Scholar
• FOUCHER J, CHANTELOUP E, VERGNIOL J et al.: Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut (2006) 55:403-408.
   PubMed Web of Science ®Google Scholar
• CASTERA L, VERGNIOL J, FOUCHER J et al.: Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology (2005) 128:343-350.
   PubMed Web of Science ®Google Scholar
• BODENHEIMER HC Jr., LINDSAY KL, DAVIS GL et al.: Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology (1997) 26:473-477.
   PubMed Web of Science ®Google Scholar
• DI BISCEGLIE AM, CONJEEVARAM HS, FRIED MW et al.: Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. (1995) 123:897-903.
   PubMed Web of Science ®Google Scholar
• SHIFFMAN ML: Treatment of chronic hepatitis C virus (HCV) genotype 1 with peginterferon α-2b (PEGIFN-), high weight based dose ribavirin (RVN) and Epoetin α (EPO) enhances sustained virological response (SVR). Presented at the 56th Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco (2005).
   Google Scholar
• SPIEGEL BM, CHEN K, CHIOU CF et al.: Erythropoietic growth factors for treatment-induced anemia in hepatitis C: a cost-effectiveness analysis. Clin. Gastroenterol. Hepatol. (2005) 3:1034-1042.
   PubMed Web of Science ®Google Scholar
• CASSARD B: Early predictive TDM of ribavirin in HIV-HCV coinfected patients. Presented at the 2nd International Workshop on HCV/HIV Coinfection (2006) Abstr. 26.
   Google Scholar
• RAMOS B: High ribavirin doses and early virological response in HCV/HIV co-infected patients. Presented at the 2nd International Workshop on HCV/HIV Coinfection (2006) Abstr. 36.
   Google Scholar
• AUGUST-JORG BS, BOROVICKA J, DUFOUR JF et al.: Twenty-four versus forty-eight weeks of retherapy with interferon α 2b and ribavirin in interferon α monotherapy relapsers with chronic hepatitis C. Swiss Med. Wkly (2003) 133:455-460.
   PubMed Web of Science ®Google Scholar
• STEINDL-MUNDA P, FERENCI P, BRUNNER H et al.: Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy. Liver Int. (2003) 23:269-275.
   PubMed Web of Science ®Google Scholar
• MOSKOVITZ DN, MANOHARAN P, HEATHCOTE EJ: High dose consensus interferon in nonresponders to interferon α-2b and ribavirin with chronic hepatitis C. Can. J. Gastroenterol. (2003) 17:479-482.
   PubMed Web of Science ®Google Scholar
• POYNARD T, MARCELLIN P, BISSERY A et al.: Reinforced interferon α-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial. J. Viral Hepat. (2003) 10:197-204.
   PubMed Web of Science ®Google Scholar
• FARGION S, BRUNO S, BORZIO M et al.: Sustained response to combination therapy in patients with chronic hepatitis C who failed to respond to interferon. J. Hepatol. (2003) 38:499-505.
   PubMed Web of Science ®Google Scholar
• HOOFNAGLE JH, GHANY MG, KLEINER DE et al.: Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon α and ribavirin. Hepatology (2003) 38:66-74.
   PubMed Web of Science ®Google Scholar
• SHIFFMAN ML, DI BISCEGLIE AM, LINDSAY KL et al.: Peginterferon α-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 126:1015-1023.
   PubMed Web of Science ®Google Scholar
• BOUCHER EJ, JACQUELINET S, CANVA V et al.: High rate of long-term virological response after a 1-year course of interferon +/- ribavirin in chronic hepatitis C relapsers. Results of a 191 patients randomized trial. Liver Int. (2003) 23:255-261.
   PubMed Web of Science ®Google Scholar
• WRIGHT M, FORTON D, MAIN J et al.: Treatment of histologically mild hepatitis C virus infection with interferon and ribavirin: a multi-centre, randomized, controlled trial. J. Virol. (2005) 12:58-66.
   Google Scholar
• GRIEVE R, ROBERTS J, WRIGHT M et al.: Cost effectiveness of interferon (α) or peginterferon (α) with ribavirin for histologically mild hepatitis C. Gut (2006) in press.
   PubMedGoogle Scholar
• ZEUZEM S, DIAGO M, GANE E et al.: Peginterferon α-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology (2004) 127:1724-1732.
   PubMed Web of Science ®Google Scholar
• KRONENBERGER B, HERRMANN E, MICOL F et al.: Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels. Hepatology (2004) 40:1442-1449.
   PubMed Web of Science ®Google Scholar
• MAUSS S, ROCKSTROH JK: HCV/HIV-coinfection-is there a state of the art after APRICOT and RIBAVIC? J. Antimicrob. Chemother. (2005) 56:615-618.
   PubMed Web of Science ®Google Scholar
• ROCKSTROH J, MOCROFT A, SORIANO V et al.: Influence of hepatitis C virus on HIV-1 disease progression and response to highly active antiretroviral therapy. J. Infect. Dis. (2005) 192:992-1002.
   PubMed Web of Science ®Google Scholar
• EYSTER ME, DIAMONDSTONE LS, LIEN JM et al.: Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J. Acquir. Immune Defic. Syndr. (1993) 6:602-610.
   PubMed Web of Science ®Google Scholar
• ROCKSTROH JK, SPENGLER U, SUDHOP T et al.: Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am. J. Gastroenterol. (1996) 91:2563-2568.
   PubMed Web of Science ®Google Scholar
• MOCROFT A, SORIANO V, ROCKSTROH J et al.: Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS (2005) 19:2117-2125.
   PubMed Web of Science ®Google Scholar
• QURISHI N, KREUZBERG C, LUCHTERS G et al.: Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet (2003) 362:1708-1713.
   PubMed Web of Science ®Google Scholar
• CHUNG RT, ANDERSEN J, VOLBERDING P et al.: Peginterferon α-2a plus ribavirin versus interferon α-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N. Engl. J. Med. (2004) 351:451-459.
   PubMed Web of Science ®Google Scholar
• CARRAT F, BANI-SADR F, POL S et al.: Pegylated interferon α-2b versus standard interferon α-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA (2004) 292:2839-2848.
   PubMed Web of Science ®Google Scholar
• TORRIANI FJ, RODRIGUEZ-TORRES M, ROCKSTROH JK et al.: Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med. (2004) 351:438-450.
   PubMed Web of Science ®Google Scholar
• LAGUNO M, MURILLAS J, BLANCO JL et al.: Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS (2004) 18:F27-F236.
   Google Scholar
• MAUSS S, VALENTI W, DEPAMPHILIS J et al.: Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS (2004) 18:F21-F25.
   PubMed Web of Science ®Google Scholar
• TOVO PA, LAZIER L, VERSACE A: Hepatitis B virus and hepatitis C virus infections in children. Curr. Opin. Infect. Dis. (2005) 18:261-266.
   PubMed Web of Science ®Google Scholar
• STEININGER C, KUNDI M, JATZKO G et al.: Increased risk of mother-to-infant transmission of hepatitis C virus by intrapartum infantile exposure to maternal blood. J. Infect. Dis. (2003) 187:345-351.
   PubMed Web of Science ®Google Scholar
• MOK J, PEMBREY L, TOVO PA, NEWELL ML: When does mother to child transmission of hepatitis C virus occur? Arch. Dis. Child. Fetal Neonatal Ed. (2005) 90:F156-F160.
   PubMed Web of Science ®Google Scholar
• RESTI M, AZZARI C, GALLI L et al.: Maternal drug use is a pre-eminent risk factor for mother-to-child hepatitis C virus transmission: results from a multicenter study of 1372 mother-infant pairs. J. Infect. Dis. (2002) 185:567-572.
   PubMed Web of Science ®Google Scholar
• JAECKEL E, CORNBERG M, WEDEMEYER H et al.: Treatment of acute hepatitis C with interferon α-2b. N. Engl. J. Med. (2001) 345:1452-1457.
   PubMed Web of Science ®Google Scholar
• NOMURA H, SOU S, TANIMOTO H et al.: Short-term interferon-α therapy for acute hepatitis C: a randomized controlled trial. Hepatology (2004) 39:1213-1219.
   PubMed Web of Science ®Google Scholar
• GERLACH JT, DIEPOLDER HM, ZACHOVAL R et al.: Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology (2003) 125:80-88.
   PubMed Web of Science ®Google Scholar
• NEUMANN UP, BERG T, BAHRA M et al.: Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation (2004) 77:226-231.
   PubMed Web of Science ®Google Scholar
• ABDELMALEK MF, FIRPI RJ, SOLDEVILA-PICO C et al.: Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl. (2004) 10:199-207.
   PubMed Web of Science ®Google Scholar
• CHALASANI N, MANZARBEITIA C, FERENCI P et al.: Peginterferon α-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology (2005) 41:289-298.
   PubMed Web of Science ®Google Scholar
• THOMAS RM, BREMS JJ, GUZMAN-HARTMAN G et al.: Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl. (2003) 9:905-915.
   PubMed Web of Science ®Google Scholar
• GISH RG: Treating HCV with ribavirin analogues and ribavirin-like molecules. J. Antimicrob. Chemother. (2006) 57:8-13.
   PubMed Web of Science ®Google Scholar
• LIN CC, PHILIPS L, XU C, YEH LT: Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers. J. Clin. Pharmacol. (2004) 44:265-275.
   PubMed Web of Science ®Google Scholar
• GISH RG, ARORA S, NELSON D: End-of-treatment response in therapy-naive patients treated for chronic hepatitis C with viramidine in combination with pegylated interferon a-2a. Abstracts of the 55th Annual Meeting of the American Association for the study of Liver Diseases (2004) Abstr. 519:388A.
   Google Scholar
• GISH RG, ARORA S, NELSON D: Safety and efficacy of viramidine in combination with pegylated interferon α-2a for the treatment of hepatitis C in therapy-naive patients. Abstracts of the 39th Annual Meeting of the European Association for the Study of the Liver (2004) Abstr. 479:141-142.
   Google Scholar
• DE FRANCESCO R, MIGLIACCIO G: Challenges and successes in developing new therapies for hepatitis C. Nature (2005) 436:953-960.
   PubMed Web of Science ®Google Scholar
• REISER M, HINRICHSEN H, BENHAMOU Y et al.: Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology (2005) 41:832-835.
   PubMed Web of Science ®Google Scholar
• CARRAT F, BANI-SADR F, POL S et al.: Pegylated interferon α-2b versus standard interferon α-2b plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA (2004) 292(23):2839-2848
   PubMed Web of Science ®Google Scholar